Ultime notizie per Zura Bio (NASDAQ:ZURA) Azioni

Zura Bio

Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.

Zura Bio Limited - Class A Ordinary shares

Zura Bio Ltd

Oppenheimer analyst Rick Schafer maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Outperform and lowers the price target from $330 to $300.

News

Price Target

Analyst Ratings

NXPI

Oppenheimer Maintains Outperform on NXP Semiconductors, Lowers Price Target to $300

FREYR Battery (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FREY#NYSE">FREY</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent.

Earnings

Earnings Misses

FREY

FREYR Battery Q3 2024 GAAP EPS $(0.20) Misses $(0.18) Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy and maintains $35 price target.

Reiteration

STOK

HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target

WIIM

PACS

PACS Group shares are trading lower after the company announced postponement of Q3 results and disclosure on civil investigative demands from the federal government.

Guidance

Freyr Provides 2025 EBITDA Guidance Of $75M - $125M, Expects To Exit 2025 At Full-year Run Rate EBITDA Of $175M - $225M

Freyr Battery Announced An Agreement To Acquire The U.S. Solar Manufacturing Assets Of Trina Solar Co Ltd. For Total Consideration Of $340M

National Vision Holdings Reiterates FY24 Outlook: Sees Revenues Of $1.820B-$1.840B Vs. $1.840B Estimate, With Adjusted EPS Of $0.45 - $0.50 Vs. $0.48 Estimate

Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) sees Q4 sales to be up 5 to 7% year-over-year.

KPLT

Katapult Holdings Sees 5 to 7% year-over-year increase in revenue for Q4.

PACS Group Preliminary Q3 Total Facilities Occupancy 90.5%, Expects To Have Ended Quarter With More Than $600M Of Cash And Available Liquidity

2024 EARNINGS GUIDANCE
LXP now estimates that its net income attributable to common shareholders for the year ended December 31, 2024 will be within an expected range of $0.14 to $0.15 per diluted common share. LXP is tightening its estimated Adjusted Company FFO for the year ended December 31, 2024, to be within an expected range of $0.63 to $0.64 per diluted common share. This guidance is forward looking, excludes the impact of certain items and is based on current expectations.

LXP Industrial Trust Narrows FY24 AFFO Guidance from $0.62-$0.65 to $0.63-$0.64 vs $0.63 Est

PACS Group Reveals Postponement Of Release Of Q3 Results; Says It Received Civil Investigative Demands From Federal Government Regarding Reimbursement And Referral Practices

LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $85.57 million which beat the analyst consensus estimate of $84.98 million by 0.69 percent. This is a 0.17 percent increase over sales of $85.42 million the same period last year.

Earnings Beats

LXP Industrial Trust Q3 AFFO $0.16, Inline, Sales $85.57M Beat $84.98M Estimate

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) with a Buy and maintains $29 price target.

NRIX

Needham Reiterates Buy on Nurix Therapeutics, Maintains $29 Price Target

Contracts

Tutor Perini, In A Joint Venture With O&G Industries, Has Been Identified As The Apparent Selected Proposer By The New York City Department Of Design And Construction For The New Manhattan Jail Facility

Needham analyst Quinn Bolton maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $96 to $85.

MCHP

Needham Maintains Buy on Microchip Technology, Lowers Price Target to $85

Management

IRBT

iRobot Chief Financial Officer Julie Zeiler To Retire, Effective December 2, 2024; Karian Wong To Succeed Zeiler As Finance Chief

Health Care

General

ENOV

Enovis Expects 2024 Adjusted EPS Of $2.75-$2.80 Versus Prior Expectations Of $2.62-$2.77 And Consensus Of $2.71

National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 100 percent. The company reported quarterly sales of $451.515 million which beat the analyst consensus estimate of $451.469 million by 0.01 percent. This is a 2.89 percent increase over sales of $438.820 million the same period last year.

National Vision Holdings Q3 2024 Adj. EPS $0.12 Beats $0.06 Estimate, Sales $451.515M Beat $451.469M Estimate

Enovis Narrowed Its Revenue Range And Adjusted  EBITDA  Expectations For 2024, With Sales Estimated At $2.1B Vs. $2.11B Est. And Adjusted EBITDA Of $373M-$378M Versus Prior Guidance Of $368M-$383M

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) with a Buy and maintains $140 price target.

PCVX

Needham Reiterates Buy on Vaxcyte, Maintains $140 Price Target

Zura Bio (ZURA) has provided an update. Zura Bio Limited has navigated a CEO transition, with Someit Sidhu stepping down and Robert Lisicki taking ...

Zura Bio Announces CEO Transition and Executive Compensation Details

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Zura Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/zura-stock-quote/">ZURA</a>) just reported results for the second quarter of 2024.<ul><li>Zura Bio reported earnings per share of -17 cents. This was below the analyst estimate for EPS of -15 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/zura-stock-earnings-zura-bio-for-q2-of-2024/">ZURA Stock Earnings: Zura Bio Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZURA Stock Earnings: Zura Bio Misses EPS for Q2 2024

Zura Bio GAAP EPS of -$0.17

Zura Bio (ZURA) has shared an announcement. Zura Bio Limited (ZURA) has released a press statement, emphasizing that the act of sharing this inform...

Zura Bio Clarifies Legal Status of Information Release

Zura Bio files for $300M mixed securities shelf

Zura Bio ( ($ZURA) ) has shared an announcement. Zura Bio Limited recently updated its corporate presentation, showcasing their promising biologic ...

Zura Bio Unveils Future Strategy and Biologic Pipeline Update

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Universal Health (UHS – Research Report), Apellis ...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Universal Health (UHS), Apellis Pharmaceuticals (APLS) and Zura Bio (ZURA)

The latest update is out from Zura Bio ( ($ZURA) ). Zura Bio Limited, a clinical-stage immunology company, is set to engage with investors at two m...

Zura Bio to Engage in Major November Conferences

Leerink initiated coverage of Zura Bio (ZURA) with an Outperform rating and $15 price target The company has assembled an "impressive collection of...

Zura Bio initiated with an Outperform at Leerink

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Zura Bio (ZURA – Research Report) today and set a price target of $26.00. The compa...

Piper Sandler Keeps Their Buy Rating on Zura Bio (ZURA)

APLS

ZURA

Press Releases

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio to Present at Three Upcoming Investor Conferences in September

Zura Bio to Participate in Two Upcoming Investor Conferences in November

BRNS

RCUS

SGMT

SNDX

TRVN

Abeona Therapeutics

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Zura Bio

Notizie

Ultime notizie per Zura Bio (NASDAQ:ZURA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO